These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 26345542

  • 1. Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Leys E, Tuttle S, Rasquin F, Neu F, Postelmans L.
    J Fr Ophtalmol; 2015 Oct; 38(8):709-16. PubMed ID: 26345542
    [Abstract] [Full Text] [Related]

  • 2. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S.
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [Abstract] [Full Text] [Related]

  • 3. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
    Cornut PL, Quaranta-El Maftouhi M, Mauget-Faÿsse M.
    J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
    [Abstract] [Full Text] [Related]

  • 4. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
    Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF, Macula Society CSC Collaborative Study Group, Research and Education Committee and Website Committee.
    Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
    [Abstract] [Full Text] [Related]

  • 5. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
    Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H.
    Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
    [Abstract] [Full Text] [Related]

  • 6. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK, Chang CK, Peng CH.
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [Abstract] [Full Text] [Related]

  • 7. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H.
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [Abstract] [Full Text] [Related]

  • 8. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F.
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [Abstract] [Full Text] [Related]

  • 9. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF, Espinoza JV.
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [Abstract] [Full Text] [Related]

  • 10. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V, Vysloužilová D, Uher M.
    Semin Ophthalmol; 2018 Aug; 33(5):690-699. PubMed ID: 29252091
    [Abstract] [Full Text] [Related]

  • 11. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
    Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F.
    Am J Ophthalmol; 2010 Feb; 149(2):307-315.e2. PubMed ID: 19896635
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study.
    Breukink MB, Mohabati D, van Dijk EH, den Hollander AI, de Jong EK, Dijkman G, Keunen JE, Hoyng CB, Boon CJ.
    Acta Ophthalmol; 2016 Sep; 94(6):565-72. PubMed ID: 27149889
    [Abstract] [Full Text] [Related]

  • 13. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M.
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [Abstract] [Full Text] [Related]

  • 14. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Reibaldi M, Boscia F, Avitabile T, Uva MG, Russo A, Zagari M, Occhipinti F, Russo V, Reibaldi A, Longo A.
    Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK, Kim K, Kim ES, Yu SY.
    Ophthalmologica; 2019 Jun; 241(2):105-115. PubMed ID: 30110697
    [Abstract] [Full Text] [Related]

  • 16. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V, Purtskhvanidze K, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.
    Smretschnig E, Hagen S, Glittenberg C, Ristl R, Krebs I, Binder S, Ansari-Shahrezaei S.
    Eye (Lond); 2016 Jun; 30(6):805-11. PubMed ID: 26965012
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
    Smretschnig E, Ansari-Shahrezaei S, Moussa S, Glittenberg C, Krebs I, Binder S.
    Retina; 2012 Jun; 32(10):2014-9. PubMed ID: 22466482
    [Abstract] [Full Text] [Related]

  • 20. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Gregório T, Cachulo ML, Pires IA, Cunha-Vaz JG, Murta JN.
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.